They are similar dendritic methods, not the same and NWBO does not have the rights to anything aside from DCVax L
Approximately 10–15 biotech/pharmaceutical companies are actively developing or have developed dendritic cell (DC) vaccines for cancer, with a larger number of academic institutions and universities (dozens worldwide) conducting research and clinical trials, often investigator-initiated.Key CompaniesNotable companies include:Dendreon Pharmaceuticals — Provenge (sipuleucel-T), the only FDA-approved DC vaccine (autologous, for metastatic prostate cancer).
Northwest Biotherapeutics (NWBO) — DCVax-L (autologous, primarily for glioblastoma).
Diakonos Oncology — DOC1021 (autologous, in trials for glioblastoma, pancreatic cancer, and others; multiple fast-track designations).
Mendus (formerly Immunicum/DCprime) — Vididencel (allogeneic/off-the-shelf, in trials for ovarian cancer and other solid tumors).
Others mentioned in pipelines: Argos Therapeutics, ImmunoCellular Therapeutics, Elios Therapeutics, DanDrit Biotech, DCPrime (merged into Mendus), and historical ones like Activartis or Batavia Bioservices.
The field is niche, with most beyond Provenge still in early-mid clinical stages.Universities and Academic CentersMany more universities and cancer centers are involved through academic trials (often autologous, personalized vaccines):UCLA ? Brain tumors (glioblastoma).
Moffitt Cancer Center ? Breast, kidney, and HER3-targeted.
Baylor College of Medicine ? Pancreatic and others.
Harvard University/Wyss Institute ? Biomaterial-based (WDVAX for melanoma).
UC San Diego ? Various solid tumors.
Others: Duke University, University of Pittsburgh, and international sites in Europe/Asia.
Clinical trial databases show hundreds of DC vaccine studies historically, with 50+ vaccines in pipelines as of recent reports (2025–2026), spanning cancers like glioblastoma, melanoma, prostate, ovarian, pancreatic, lung, and AML. Most are autologous (patient-specific), but allogeneic/off-the-shelf approaches are growing for scalability.The exact count varies by definition (active commercial development vs. any research/trial), but commercial efforts are led by a handful of companies, while academic/university work is widespread and drives much of the innovation. The market is expanding, with projections for growth through 2035 due to combinations with checkpoint inhibitors and improved manufacturing.
AI
